Milestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved ...
MedPage Today on MSN
Unprecedented PFS in HER2-Mutant Lung Cancer, but With a Touch of Controversy
Practice-changing median of 14.3 months with T-DXd, but caution over early unfavorable OS ...
New results from the global Phase I/II ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) ...
Nuvation Bio (NYSE:NUVB) presented new subgroup analyses of IBTROZI (taletrectinib) at the 2026 World Conference on Lung ...
Gotistobart continues to show potential aschemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with ...
The FDA has granted accelerated approval to sevabertinib as first-line treatment for adults with locally advanced or ...
InvestorsHub on MSN
BioNTech Shares Rise 6.4% After Updated Gotistobart Lung Cancer Trial Data
BioNTech SE (NASDAQ:BNTX) shares rose 6.4% in pre-market trading on Monday after the company reported updated survival data ...
Everyday Health on MSN
How to cope with anxiety when you have metastatic non-small-cell lung cancer
Anxiety is common in people living with metastatic non–small-cell lung cancer, and it can interfere with treatment. Get tips ...
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the ...
NSCLC treatment is stage-dependent, involving surgery, chemotherapy, radiation, immunotherapy, and targeted therapy based on tumor genetics. Molecular profiling is essential for personalized treatment ...
BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results